DIZINIL 20/TAB

Indications

Approved Uses

Prevention and treatment of nausea, vomiting, dizziness, and vertigo associated with motion sickness

Off-Label Uses

Vertigo/vestibular disturbances (including Ménière’s-associated nausea); postoperative nausea/vomiting (setting-dependent).

Dosage & Administration

Dosing by Condition

Motion sickness (adults): 50-100 mg orally every 4-6 hours as needed; take first dose 30-60 minutes before travel; maximum 400 mg/day.

Initial Dose

50-100mg (1-2 tablets) 30 minutes before travel or onset of symptoms

Maintenance Dose

50-100 mg every 4-6 hours as needed.

Maximum Dose

400 mg per 24 hours.

Children's Dosage

Children 2-6 years: 12.5-25mg every 6-8 hours (max 75mg/day); Children 6-12 years: 25-50mg every 6-8 hours (max 150mg/day); Children over 12 years: adult dose. Not recommended under 2 years

How to Take

Oral tablet: swallow with water; may be taken with or without food. For motion sickness prevention, take the first dose 30-60 minutes before travel/activity; repeat doses may be taken every 4-6 hours as needed within the daily maximum.

Side Effects

Common Side Effects

Drowsiness/sedation, dizziness, dry mouth, blurred vision, constipation; may also cause urinary retention (especially in susceptible patients).

Safety & Warnings

Contraindications

Hypersensitivity to dimenhydrinate/diphenhydramine (or excipients); neonates/premature infants; narrow-angle (angle-closure) glaucoma; urinary retention/bladder neck obstruction (including BPH); pyloric/duodenal obstruction.

Warnings & Precautions

May cause significant drowsiness-avoid driving/operating machinery and avoid alcohol/other sedatives; use caution in elderly (confusion/falls/urinary retention), seizure disorders, asthma/COPD or other lower respiratory disease (thickened secretions), angle-closure glaucoma, and prostatic enlargement/urinary retention; may mask ototoxicity symptoms from aminoglycosides; paradoxical excitation may occur in children.

Age Restriction

Not recommended for children under 2 years of age unless directed by a doctor.

Drug Interactions

Drug Interactions

CNS depressants (alcohol, benzodiazepines, opioids, barbiturates) increase sedation; MAO inhibitors may prolong/intensify anticholinergic/CNS effects; other anticholinergics/first-generation antihistamines and TCAs cause additive anticholinergic effects; may mask ototoxicity symptoms of aminoglycosides.

Interaction Severity

MAJOR: other CNS depressants (including alcohol, benzodiazepines, opioids) due to additive sedation/respiratory/CNS depression risk. MODERATE: MAO inhibitors and other anticholinergic drugs (e.g., tricyclic antidepressants) due to potentiation of anticholinergic/CNS effects; aminoglycosides (may mask ototoxicity symptoms).

Food Interaction

No specific food restrictions; may be taken with or without food.

Special Populations

Children

Children 2-6 years: 12.5-25mg every 6-8 hours (max 75mg/day); Children 6-12 years: 25-50mg every 6-8 hours (max 150mg/day); Children over 12 years: adult dose. Not recommended under 2 years

Storage & Patient Advice

Storage Conditions

Store at 15° to 30°C (59° to 86°F)

Stopping the Medicine

Safe to stop anytime; no tapering required for short-term/PRN use.

Patient Counseling

May cause significant drowsiness-avoid driving/operating machinery until effects are known; avoid alcohol and other sedatives. For prevention, take 30-60 minutes before travel; do not exceed 100 mg per dose or 400 mg/day. Use caution/seek advice if you have glaucoma, urinary retention/BPH, asthma/COPD, or are elderly; keep out of reach of children.

Monitoring Requirements

No routine monitoring required for short-term use

Pharmacology

Mechanism of Action

Competitive H1 receptor antagonism with central anticholinergic (antimuscarinic) activity; reduces vestibular stimulation and depresses signaling to the vomiting center/CTZ, decreasing nausea and motion-sickness symptoms.

Onset of Action

About 15-30 minutes after oral administration.

Duration of Effect

Approximately 4-6 hours.

Half-Life

Approximately 3.5-9 hours (commonly cited range; often ~5-8 hours in adults).

Bioavailability

Well absorbed after oral administration (absolute bioavailability not well defined).

Metabolism

Extensively metabolized in the liver (hepatic metabolism).

Protein Binding

Approximately 70-85% (commonly cited; ~78% reported for the diphenhydramine component).

Product Information

Available Dosage Forms

Tablet

Composition per Dose

Each tablet: 50mg dimenhydrinate (equivalent to 35.5mg diphenhydramine and 14.5mg 8-chlorotheophylline)

Generic Availability

Yes

OTC Alternatives

Meclizine and diphenhydramine (OTC in many regions) for motion sickness; non-drug options include ginger and behavioral measures.

Gi Condition

Nausea/Vomiting

Legal Disclaimer - Al Mujtama Pharmacy

The product information provided is derived from verified pharmaceutical references and is intended for general health education only. It is not a substitute for professional medical advice, diagnosis, or treatment.

Al Mujtama Pharmacy assumes no legal or medical liability for:

• Any therapeutic decision made based on the information displayed without consulting a licensed physician or pharmacist
• Any discrepancy between the information provided and the product's package insert or SFDA guidelines
• Any misuse of medication resulting from personal interpretation of the content displayed

Important notice: Drug formulations and instructions may vary between production batches. Always rely on the leaflet included inside the product packaging you have, and consult your pharmacist or physician before starting, adjusting, or discontinuing any medication.

By using this content, you acknowledge that you have read this disclaimer and agree that Al Mujtama Pharmacy bears no liability arising from reliance on this information as a substitute for direct medical consultation.

Your health is a trust - always consult your doctor first.